PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Company ReportsSpringWorks Therapeutics
SpringWorks Therapeutics(SWTX)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Loading
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Plot placeholder
Mock data
Subscribe for the real data
Revenue by Drug
Loading
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
OgsiveoNirogacestat2023-11-272025-2043
Desmoid tumors
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
MIRDAMETINIB
healthy volunteers/patients
,
lung neoplasms
,
hepatic insufficiency
,
neoplasms
,
neurofibromatoses
,
non-small-cell lung carcinoma
,
neurofibromatosis 1
,
neurofibroma
,
colorectal neoplasms
,
plexiform neurofibroma
,
breast neoplasms
,
melanoma
,
glioma
,
colonic neoplasms
,
astrocytoma
,
oligodendroglioma
,
ganglioneuroma
,
ganglioglioma
,
neuroepithelial neoplasms
,
neurocytoma
,
triple negative breast neoplasms
,
neoplasm metastasis
,
vascular malformations
,
vascular skin diseases
,
arteriovenous malformations
,
lymphangioma
,
lymphatic abnormalities
,
cystic lymphangioma
,
histiocytosis
,
langerhans-cell histiocytosis
,
juvenile xanthogranuloma
,
sinus histiocytosis
,
liposarcoma
,
myxoid liposarcoma
,
multiple myeloma
,
b-cell chronic lymphocytic leukemia
,
glioblastoma
,
central nervous system neoplasms
,
autonomic nervous system diseases
,
histiocytic sarcoma
Nirogacestat
healthy volunteers/patients
,
leukemia
,
neoplasms by histologic type
,
multiple myeloma
,
neoplasms
,
breast neoplasms
,
plasma cell neoplasms
,
kaposi sarcoma
,
triple negative breast neoplasms
,
pancreatic neoplasms
,
sarcoma
,
hiv infections
,
hematologic diseases
,
blood protein disorders
,
paraproteinemias
,
corneal diseases
,
ovarian neoplasms
,
granulosa cell tumor
,
fibroma
,
aggression
,
desmoid tumors
LIFIRAFENIB
neoplasms
Nepidermin
healthy volunteers/patients
,
pancreatic neoplasms
,
brain neoplasms
,
glioma
,
pharyngeal neoplasms
,
tonsillar neoplasms
,
neoplasms
,
melanoma
,
head and neck neoplasms
,
colorectal neoplasms
,
rectal neoplasms
,
skin neoplasms
,
renal cell carcinoma
,
carcinoma
,
myelodysplastic syndromes
,
preleukemia
,
syndrome
,
diabetic retinopathy
,
glioblastoma
,
gliosarcoma
,
colonic neoplasms
,
squamous cell carcinoma
,
kidney neoplasms
,
systemic scleroderma
,
lung diseases
,
interstitial lung diseases
,
localized scleroderma
,
diffuse scleroderma
,
sarcoma
,
hemangiosarcoma
,
hereditary sensory and autonomic neuropathies
,
breast neoplasms
,
lung neoplasms
,
non-small-cell lung carcinoma
,
macular edema
,
lupus nephritis
,
systemic lupus erythematosus
,
lymphoma
,
chronic urticaria
,
triple negative breast neoplasms
,
ovarian neoplasms
,
fallopian tube neoplasms
,
non-hodgkin lymphoma
,
diabetes mellitus
,
vision disorders
,
retinal vein occlusion
,
edema
,
central venous catheters
,
stomach neoplasms
,
adenocarcinoma
,
ovarian epithelial carcinoma
,
neoplasm metastasis
,
rheumatoid arthritis
,
nephritis
,
macular degeneration
,
follicular lymphoma
,
thrombosis
,
hemophilia a
,
intracranial hemorrhages
,
cerebral hemorrhage
,
cerebral intraventricular hemorrhage
,
b-cell lymphoma
,
asthma
Endocrine
type 2 diabetes mellitus
,
diabetes mellitus
,
insulin resistance
,
obesity
,
inflammation
,
hypoglycemia
,
type 1 diabetes mellitus
,
liver diseases
Pd0332991
liposarcoma
,
myxoid liposarcoma
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use